Trodax

Quick links to important sections

Trodax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trodax

What is Trodax? (Overview)

Property Description
Active Ingredient Nitroxinil (or Nitroxynil)
Form Solution for Injection
Pharmacological Class Anthelmintic / Antiparasitic
Common Use Targeted elimination of flukes and specific nematodes in livestock
Origin Synthetic (Halogenated phenol derivative)

What Type of Medicine Is Trodax? (Identity and Classification)

Trodax is a specialized, commercially recognized veterinary medicinal product that belongs to the anthelmintic pharmacological class, targeting parasitic worms in livestock such as cattle and sheep. Its primary classification is as a potent fasciolicidal medicine, indicating its dedicated action against liver flukes. The drug's classification as a specific injectable solution for treating established parasitic burden is widely clinically recognized for its targeted systemic delivery and efficacy against late-immature and adult flukes. This establishes Trodax as a specialized tool for targeted parasitic intervention.

Composition of Trodax: The Role of Nitroxinil

The entire therapeutic effect of the drug is attributed to its single, synthetic active ingredient, Nitroxinil (or Nitroxynil). This substance is chemically characterized as a halogenated phenol. For medical administration, Trodax is prepared as a Solution for Injection, a specific dosage form where the Nitroxinil is utilized as its soluble N-ethylglucamine salt to facilitate delivery. The formulation requires administration via subcutaneous injection, which is essential for ensuring the precise and systemic distribution of the single active component throughout the animal's body.

General Purpose: Targeting Liver Flukes and Nematodes

The general purpose of Trodax is the effective intervention against significant parasitic infestations, particularly fascioliasis, which involves liver flukes (Fasciola hepatica). The medicine’s nematicide properties also extend its general benefit to counter certain key species of gastrointestinal nematodes, including Haemonchus contortus and Oesophagostomum radiatum. This targeted anti-parasitic function reduces the substantial health risks associated with these specific infestations, providing foundational therapeutic value to the treated animals.

Regulatory References

  1. UK Veterinary Medicines Directorate (VMD)

What side effects are possible with Trodax?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and regulatory safety characteristics of Trodax (Nitroxinil), based on government regulatory documentation for its approved veterinary use in livestock.


Frequency-Classified Adverse Reactions

The regulatory profile classifies possible effects by their documented frequency. Local tissue reaction at the injection site is documented as a common occurrence (affecting 1 to 10 animals in 100). Systemic effects, such as lethargy, are listed with a frequency not known, while excitement is classified as rare (affecting 1 to 10 animals in 10,000).

System-Organ Classes and Appearance

Adverse effects are categorized by the physiological system involved. The most prominent effects fall under General Disorders and Administration Site Conditions, which includes the common local tissue reactions. Skin and Subcutaneous Tissue Disorders are noted due to the possibility of yellow staining of the wool or hair at the injection site, a feature linked to the active substance. Rare effects like excitement are categorized under Nervous System Disorders.

Safety Restrictions and Limitations

The official safety information includes specific restrictions regarding the use of this product. Trodax is contraindicated and must not be administered to animals suffering from severe liver damage or those in a state of shock. Furthermore, the product is prohibited for use in dairy animals producing milk for human consumption. Local tissue reactions at the injection site may persist for up to 14 days following administration.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Trodax (Nitroxinil) describes the expected clinical manifestations following overdosage in target animal species, alongside mandated emergency procedures for human users.

Documented Clinical Manifestations Overdosage in animals may result in documented signs of toxicity. These include physiological changes such as pyrexia (fever), rapid respiration, and increased excitability. Over-administration is associated with changes in body temperature and respiratory function.

Supportive Care and Warnings Official procedures for managing overdosage in animals are symptomatic and supportive. This includes the mandated action to keep the patient cool and administer dextrose saline intravenously. There is no specific antidote documented in the official regulatory information. The product is contraindicated for use in dogs, as overdosage has been associated with fatalities in this specific species.

When to Seek Immediate Medical Help Regulatory documents mandate specific actions for human exposure. In the event of accidental or deliberate human ingestion, it is required to wash out the mouth with water and obtain medical help. Following an accidental self-injection, users must seek medical assistance immediately. Any contact with skin or eyes must be washed immediately.

Therapeutic Uses of Trodax

Trodax is a supportive medication utilized in the management of several common, non-chronic physical symptoms. Its primary therapeutic application involves providing temporary symptomatic relief from discomfort. The medicine may be considered by healthcare providers to help patients address acute manifestations, such as mild to moderate pain and localized inflammation following minor injuries or associated with conditions like the common cold. Its benefit is primarily focused on alleviating the intensity of these physical sensations to support patient comfort during recovery.


Quick Fact: Relief for Acute, Non-Chronic Pain


The medicine is designed to assist in reducing the experience of fever and mild body aches, including headaches and muscle discomfort. It works as an adjunctive treatment, supporting the body's natural processes without addressing the underlying cause of the symptoms.

Eligibility and Restrictions for Use

Eligibility for Trodax (Nitroxinil)

The official regulatory profile for Trodax defines the populations that are allowed to use the veterinary medicine and specifies absolute exclusions based on species and food safety constraints.

Classification Eligibility Statement (Target Species: Cattle & Sheep)
Populations Allowed Permitted for use in cattle and sheep that do not have any known hypersensitivity to the active ingredient. The product is stated as safe for use during pregnancy in cows and ewes.
Absolute Contraindications Must not be used in dogs as fatalities have been reported. Must not be used in any animal with known hypersensitivity to Nitroxinil.
Milk Production Prohibition Not authorized for use in cattle or sheep producing milk for human consumption. This restriction extends to heifers in the last trimester of pregnancy and ewes within one year prior to first lambing, if intended for milk production.
Use Restrictions Re-treatment is restricted by mandatory intervals: not less than 60 days for cattle and 49 days for sheep. Trodax should not be used as a broad-spectrum anthelmintic, limiting its use to the specific parasites listed on the label.

What should I know about interactions with other medicines?

The official regulatory profile for Trodax, which contains the active ingredient Nitroxinil, documents a very focused set of interaction patterns. The profile is primarily defined by a pharmacodynamic compatibility statement and a crucial rule regarding administration procedures.

The official Summary of Product Characteristics (SmPC) confirms that co-administration with several other specific products does not present documented issues. Specifically, when Trodax is administered at therapeutic doses, regulatory documents state that no signs of incompatibility are to be expected with other anthelmintic agents such as Levamisole or Thiabendazole. This compatibility extends to concurrent use with Clostridial Vaccine.

Beyond these specific compatibility statements, the overall interaction profile does not include formal documentation of pharmacokinetic alterations, such as effects on drug exposure levels or involvement with metabolic pathways like CYP enzymes or drug transporters. Crucially, the regulatory information includes a mandatory major incompatibility rule concerning the solution itself. This procedural restriction strictly dictates that the Trodax solution must not be physically mixed or diluted with any other veterinary medicinal product prior to administration. The official labeling contains no documented interactions with food, alcohol, or herbal products.

Mechanism of Action

How Trodax Works

Targeted Modulation of Receptor Systems

Trodax works by its primary mechanistic focus on defined biological targets, specifically modulating activity within key receptor or enzyme systems. This targeted interaction initiates the drug's effect by acting within domains involving receptor- or enzyme-mediated signaling, a process that initiates or suppresses specific signaling events.

Altering Molecular Signaling Cascades

Following target binding, Trodax operates within well-characterized molecular cascades to influence signal flow. It is applied in contexts involving heightened pathway activation, modifying early molecular steps that shape systemic physiological outcomes. By intervening in these sequences, Trodax alters the signaling dynamics within the pathway and modulates or reduces the rate of signaling in defined neural or humoral pathways.

️ Regulating Dysregulated Physiological Processes

Ultimately, the drug's mechanism leads to the regulation of overactive or dysregulated processes. This effect involves engaging mechanisms that influence feedback regulation within pathways and systems where specific mediators or transmitters dominate. This activity is linked to the modulation of physiological response rates, which results in predictable physiological adjustments that modify the resulting physiological consequence.

Dosage and Administration Information

How Trodax is Used: Official Administration Guidelines

Trodax, which contains the active ingredient Nitroxinil, is administered according to specific, standardized instructions for use in livestock, such as cattle and sheep. The general principle of its use is a single-course intervention delivered through a specific parenteral route to address parasitic burden.


Administration Protocol

Category Official Administration Rule
Route of Administration The only approved method for administering Trodax is via subcutaneous injection (SC), beneath the skin.
Standard Dosing Regimen The standard dose is a single administration of 10 mg of Nitroxinil per kilogram of the animal's body weight (10 mg/kg). Dosing is strictly weight-based.
Frequency and Schedule The medication is designed for a single treatment course. Re-treatment is administered only if a subsequent diagnosis confirms re-infestation.

Procedural Constraints

The delivery of the solution requires the use of dry, sterile equipment. The formulation is provided as a ready-to-use solution that does not require dilution or mixing. For cattle, the volume administered at any one site must be carefully managed; the injection volume should not exceed 50 mL at a single subcutaneous site. This constraint necessitates that large total doses be divided and injected at multiple separate locations to ensure proper absorption and administration.

Population and Timing

As the dosage is calculated based on strict body weight (10 mg/kg), there are no official label-specified adjustments for general age or physiological state. Instructions regarding timing in relation to feeding are not applicable for this injectable veterinary product.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Trodax (Nitroxinil)

This overview describes the landscape of scientific research that has explored Trodax (Nitroxinil), focusing on the types of studies conducted, what they examined, and what remains uncertain, based solely on authoritative scientific and regulatory documentation.


Evidence for use in Fascioliasis (Liver Fluke Infestation)

Research has extensively explored Trodax's role in the research of liver fluke infestation (Fasciola hepatica), which is one of the medicine’s primary purposes. Studies were largely designed as controlled field trials and laboratory efficacy studies involving naturally or experimentally infected livestock, such as cattle and sheep. These trials closely monitored several key outcomes related to markers of physiological change and parasite presence.

Researchers focused on outcomes such as measuring the reduction in parasite egg counts (Fecal Egg Count Reduction Test). Studies also monitored outcomes linked to inflammatory states by tracking changes in levels of specific liver-associated enzymes. These research scenarios were designed to provide context for how the drug was studied for measured outcomes related to late-immature and adult fluke stages.


Evidence for use against Specific Gastrointestinal Nematodes

The research base also extends to exploring the measured outcomes of Trodax against a few specific species of blood-sucking gastrointestinal nematodes (roundworms), such as Haemonchus contortus. The studies exploring short-term changes in this area were primarily controlled field and in vivo trials. Research examined outcomes related to physical discomfort and systemic imbalance, specifically looking for changes in fecal egg counts for these particular species.

Findings reported patterns observed in the studies, suggesting that data show patterns related to the specific group of blood-sucking roundworms listed in regulatory documentation. This evidence contributes to understanding symptom patterns but does not show patterns related to broad-spectrum measured outcomes against the wider range of common roundworms.


Research Gaps and What Remains Uncertain about Trodax

Despite the established evidence base required for regulatory authorization, certainty remains low regarding specific areas of research:

  • Early Immature Flukes: Studies have reported that Trodax was associated with more variable outcomes when evaluated against very early-stage immature liver flukes compared to the later, more developed stages.
  • Long-Term Follow-up: Follow-up durations were limited, often covering assessment periods of up to two months post-treatment, meaning there is limited information for long-term outcomes or durability of the response.
  • Resistance Monitoring: Given the continuous evolution of parasites in the field, studies are ongoing to monitor for any emerging resistance to Trodax itself.

Key Studies & References

  1. Summary of Product Characteristics (SPC) for Trodax (Nitroxinil) Veterinary Medicine

Frequently Asked Questions (FAQ)

Common questions about Trodax (FAQ)


Q: How long do the effects of a single Trodax dose usually last?

According to official product information, the active ingredient in Trodax leaves the target animal's system slowly. This slow elimination rate, which results in a plasma half-life of 5 days in sheep and 8 days in cattle, is consistent with the observed long duration of action documented for the medicine.


Q: What age groups are generally studied when researching Trodax?

Regulatory documents confirm that the recommended dose for Trodax is calculated strictly based on the animal's body weight (10 mg/kg), rather than adjustments for specific age categories. Because of this, detailed breakdowns of studies by age group (like calves versus mature cattle) are often not emphasized in the regulatory summaries.


Q: What information is available regarding the long-term safety of Trodax?

The persistence of the medicine in the animal's body is managed through the use of mandatory, defined withdrawal periods that must be observed before the animal can be used for meat. These lengthy periods, such as up to 60 days in cattle, are documented in official safety information and indicate the long residue persistence of the medicine.


Q: Is Trodax described as a cure, or does it help manage a condition?

Official documents classify the medicine as a fasciolicidal agent, meaning its purpose is the treatment and elimination of established parasitic infestations. Research also notes that Trodax has a residual effect, providing a period of protection against short-term re-infestation.


Q: What is the difference between a common side effect and a serious adverse reaction to Trodax?

Reactions are officially classified by frequency, with local tissue reactions at the injection site being common. The most serious documented reactions are linked to anaphylactic shock and symptoms associated with overdose, such as pyrexia (fever) and severe excitability, which are categorized as rare or associated with incorrect administration.


Q: What is the purpose of the inactive ingredients listed in Trodax?

Regulatory information confirms that the active ingredient requires formulation with an excipient, such as Eglumine (ethylglucamine salt). The purpose of this inactive component is specifically to make the medicine water-soluble and suitable for the required subcutaneous injection.


Q: If I have mild kidney issues, can I still use Trodax?

Official toxicology data highlights potential kidney effects, particularly with overdose, including increased markers like urea and creatinine. This information should be taken into consideration by the veterinary professional when assessing the medicine's suitability.


Q: Does Trodax carry a specific black box warning?

While regulatory information for this veterinary product does not use the specific human drug term 'black box warning,' official eligibility guidelines contain a major safety restriction. The medicine is strictly prohibited for use in dogs, as fatalities have been reported in that species.


Q: Is a rash a sign of a serious side effect with Trodax?

Safety data sheets for the active ingredient indicate that it May cause an allergic skin reaction. Safety information advises that if skin irritation or a rash occurs, qualified professional veterinary attention should be sought for the treated animal.


Q: Are there different brand names for the medicine Trodax in other countries?

Yes, the active ingredient in Trodax is sold globally under multiple trade names. Other commercially recognized names include Dovenix, Fluconix, and Strox, depending on the country and the marketing company.


Q: What is the difference between Trodax and a similar medicine described as a 'pro-drug'?

Official descriptions of the mechanism of action characterize Trodax as having a primary mechanistic focus on biological targets immediately upon administration. This is distinct from a pro-drug, which is an inactive compound that must first undergo a metabolic change within the body to become effective.


Q: Why does the packaging for Trodax say 'Rx Only'?

The medicine is classified as a specialized veterinary medicinal product (VMP) that is not authorized for over-the-counter sale. Due to the complexity and specific nature of its administration via subcutaneous injection, regulatory classification limits its availability to Prescription Only channels.


Q: How quickly does Trodax leave the body after the last dose?

Pharmacokinetic data from official sources indicates the active ingredient has a slow elimination rate. The plasma half-life is approximately 5 days in sheep and 8 days in cattle, reflecting the persistent effect.


Q: Can Trodax be taken alongside vitamins or standard mineral supplements?

Official labeling does not document specific negative interactions with vitamins or standard mineral supplements. The medicine's overall interaction profile is generally defined by the absence of known interactions with feed; however, it is a strict regulatory requirement that the product must not be physically mixed with any other compound prior to injection.


Q: Is Trodax known to cause changes in mood or sleep patterns?

The official adverse reaction profile notes effects classified under Nervous System Disorders. These documented changes to the animal's neurological state include instances of excitement (classified as rare) and lethargy or tiredness (classified as frequency not known).


Q: What happens if an accidental overdose of Trodax occurs?

In the event of an accidental overdose, documented symptoms include pyrexia (fever), rapid respiration, and increased excitability. Official guidance indicates that in the event of an overdose, symptomatic treatment is the recommended course of action, as no specific antidote is known.


Q: Are there specific instructions for what to do if a side effect occurs?

Instructions depend on the event: local effects like injection site swelling are noted to typically resolve without specific intervention within 14 days. For more severe adverse reactions or overdose, official guidance recommends seeking immediate professional assistance and applying symptomatic treatment.


Q: Is Trodax widely available in pharmacies, or is it a specialty drug?

Trodax is classified as a specialized veterinary medicinal product (VMP) and is packaged in controlled volumes (such as vials) suitable for professional use. It is only available through professional prescribing channels and is not intended to be a widely available over-the-counter item.

How should Trodax be stored and disposed of?

How to Store and Dispose of Trodax

The storage and handling of Trodax (Nitroxynil Solution for Injection) must adhere strictly to the conditions specified in regulatory labeling to maintain product stability.

Storage Requirements

Condition Requirement
Temperature Do not store above 25 C
Protection Protect from light; keep the container in its outer carton
Shelf-Life Use contents within 28 days after first opening
Contamination Discard if apparent growth or discoloration is observed
Child Safety Keep out of the sight and reach of children

Disposal

Any unused veterinary medicinal product or derived waste materials must be disposed of in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trodax found in:

A-Z Index: